PT - JOURNAL ARTICLE AU - Raju, Reshma AU - Angelin, J Kezia AU - Karthikeyan, Arun S AU - Kumar, Dilesh AU - Kumar, Ranjith R AU - Sahai, Nikhil AU - Ramanujan, Karthik AU - Murhekar, Manoj AU - Elangovan, A. AU - Samuel, Prasanna AU - John, Jacob AU - Kang, Gagandeep TI - Healthcare utilisation survey as part of the Hybrid model of the Surveillance of Enteric Fever in India (SEFI) study: processes, results, and challenges AID - 10.1101/2021.02.27.21252424 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.27.21252424 4099 - http://medrxiv.org/content/early/2021/03/01/2021.02.27.21252424.short 4100 - http://medrxiv.org/content/early/2021/03/01/2021.02.27.21252424.full AB - Background Enteric fever is a significant health challenge in low and middle-income countries. “Surveillance of Enteric Fever in India” (SEFI) network was set up to obtain reliable incidence data. Six sites utilised a hybrid surveillance model, a combination of facility-based surveillance and community-based healthcare utilisation survey (HCUS). HCUS was performed to determine the percentage of the catchment population utilising the study facilities for febrile episodes, and is described here.Methods A two-stage sampling process was utilised for the HCUS to select 5000 households per site. Demographic data and healthcare-seeking behaviour were assessed.Results Febrile hospitalisation rate ranged from 2.5/1000 in Kullu to 9.6/1000 in Anantapur. The percentage of febrile admissions that sought care in the study hospital from the catchment area is 17% in Anantapur, 38% in Karimganj, 38% in Chandigarh, 10% in Nandurbar, 36% in Kullu and 24% in East Champaran respectively.Conclusions The variability in healthcare utilisation for fever admissions in the study hospitals underscores the importance of periodic healthcare utilisation surveys in hybrid surveillance. It is essential to adjust for those cases which have slipped out of the facility surveillance radar for obtaining an accurate estimate of the disease burden.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at http://icmje.org/disclosure-of-interest/. GK has received support from Bill and Melinda Gates Foundation, USA, for the submitted work. Other authors have no competing interest.Clinical TrialISRCTN72938224Funding StatementThis study was supported by a grant from the Bill and Melinda Gates Foundation; grant number- Investment ID INV-009497 OPP1159351Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. Approved 06/12/2017, Postgraduate Institute of Medical Education and Research Institutional Ethics Committee (Room number 6006, 6th floor, Research block B, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh, India, 160012; +91 172 2755266; iecpgi@gmail.com), ref: PGI/IEC/2018/000017 2. Approved 15/12/2017, Rural Development Trust Hospital Institutional Ethics Committee (Rural Development Trust Hospital, Bathalapalli, Anantapur, Andhra Pradesh, India, 515661;+91 9177155517; hariharanadha.sarma@gmail.com), ref: RDTHBTP/CERT/ETHICS/2018/002 3. Approved 09/03/2018, Lady Willingdon Hospital Institutional Review Board (Manali, Himachal Pradesh, India, 175131; +91 9816033110; philalex1@gmail.com), ref: LWH/IRB/CL/2018/01 4. Approved 17/11/2017, Emmanuel Hospital Association Institutional Ethics Committee (Emmanuel Hospital Association, 808/92, Deepali Building, Nehru Place, New Delhi, India, 110019; +91 8527747395; jameelageorge@eha-health.org), ref: Protocol Number 170, Version 2; Protocol number 168, Version 2; Protocol Number 173, Version 2All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData analysis is ongoing and the manuscript is under preparation. Data will be provided upon request.